Oppositional Defiant Disorder | Defiant Teenager | Defiant Kid | ADHD

Back to ADHD News List

ADHD In Adults Shire Announces Filing Of VYVANSE

Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ) has announced that it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for VYVANSE? (lisdexamfetamine dimesylate) for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adults. This application is subject to a 10-month FDA review period."ADHD is a treatable disorder that affects adults as well as children," said Matthew Emmens, Shire Chief Executive Officer. [click link for full article]

Source: http://www.medicalnewstoday.com/sections/adhd/

In schools, treatment plans are often poorly integrated. In addition, there are few special education funds directed specifically for ADHD
 

This page is about Attention deficit hyperactivity disorder (ADHD)